GlassScriptPhysician profile
Katherine E Wasek
NPI 1205237302
$8,043.94
in general payments reported to CMS, 2019-2025
28 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,269 · 2022: $1,490 · 2023: $2,058 · 2024: $1,924 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Education: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,746.83 |
| Education | $538.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,356.98 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,080.22 | 2021-2025 | |
| Lilly USA, LLC | $618.33 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $586.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $511.76 | 2021-2025 | Dupixent |
| Genzyme Corporation | $499.31 | 2021-2024 | |
| Ucb, INC. | $448.82 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $443.85 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $432.91 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $327.14 | 2021-2025 | Opzelura |
| Amgen INC. | $290.28 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $277.70 | 2021-2025 | Oracea, Nemluvio |
| Sun Pharmaceutical Industries INC. | $257.50 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $157.94 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $136.31 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $132.65 | 2023-2025 | Vtama, Hadlima |
| Pfizer INC. | $99.87 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.31 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $73.55 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.43 | 2022-2025 | Spevigo, Cyltezo |
| Almirall LLC | $30.23 | 2022-2024 | Seysara |
| Convatec INC. | $26.33 | 2025 | |
| Vyne Pharmaceuticals INC. | $25.02 | 2021 | |
| Mayne Pharma Commercial LLC | $22.25 | 2023 | |
| Verrica Pharmaceuticals INC. | $19.80 | 2024 | Ycanth |
| Shionogi INC | $17.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.43 | 2021 | |
| Journey Medical Corporation | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Wasek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.